New paper
HER3 mediates metabolic reprogramming in metastatic colorectal and pancreatic cancer
Why it was picked newest record on or before this date
The Pancreatic Cancer Research Digest
New trials, papers and changes to existing records, compiled daily from the public registries
New paper
Bile-derived RNA N6-methyladenosine (m6A) methylation as a novel liquid biopsy biomarker for pancreatic cancer
Why it was picked newest record on or before this date
New paper
ROCK2 inhibitor belumosudil overcomes resistance to KRAS inhibition in pancreatic cancer models.
Why it was picked newest record on or before this date
New paper
Longitudinal Pancreatic Imaging Findings in BRCA1, BRCA2, ATM, and PALB2 Heterozygotes Undergoing Pancreatic Cancer Surveillance: A Prospective PRECEDE Consortium Study.
Why it was picked newest record on or before this date
New paper
KRAS Inhibitor Resistance Confers a Targetable Vulnerability to Ferroptosis in Pancreatic Ductal Adenocarcinoma.
Why it was picked newest record on or before this date
Also today
New paper
Sitagliptin, a repurposed diabetes drug, overcomes gemcitabine resistance in pancreatic cancer via ribonucleotide reductase inhibition: SITGEM-CARE phase 2 trial.
New paper
Macropinocytosis in pancreatic ductal adenocarcinoma: From metabolic reprogramming to therapeutic targeting.
New paper
Association of 8 -oxoguanine DNA glycosylase (OGG1) and cytochrome P450 (CYP1A1) polymorphisms with pancreatic adenocarcinoma.
New paper
A fractal-integrated CT score predicts high-risk pathology and early recurrence in pancreatic ductal adenocarcinoma.
Change tracking began 4 November 2026. No status changes, newly posted results or retractions have been recorded on this day yet; they appear here as the nightly runs find them.
Compiled by the knowledge layer from its change log. Every headline opens the underlying record; every identifier links to its source.